1. https://www.iasp-pain.org/publications/iasp-news/iasp-announces--revised-definition-of-pain.

2. Kocot-Kępska M. Nowoczesne metody leczenia bólu przewlekłego. Lek w Polsce. 2014;24(1):46-56.

3. Pęksa J, Malinowska-Karpiel A. Farmakoterapia bólu ostrego i przewlekłego w podstawowej opiece zdrowotnej. Lek w Polsce. 2020;30 (6/7):31-42.

4. Anekar AA, Cascella M. WHO Analgesic Ladder. [Updated 2021 May 18]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/ books/NBK554435/.

5. Woroń J, Dobrogowski J, Wordliczek W, et al. Leczenie bólu w oparciu o drabinę analgetyczną WHO. Medycyna po Dyplomie. 2011;08:52-61.

6. Hylands-White N, Duarte RV, Raphael JH. An overview of treatment ap - proaches for chronic pain management. Rheumatol Int. 2017;01:29-42.

7. Krajnik M, Sobański P. Ból u chorego na nowotwór. Interna Szczeklika. https://www.mp.pl/interna/chapter/B16.II.22.1.

8. AGS clinical practice guidelines: the management of chronic pain in older persons. Geriatrics. 1998 Oct;53 Suppl 3:S6-7. PMID: 9826951.

9. Wytyczne Postępowania w bólu przewlekłym Polskiego Towarzystwa Badania Bólu i Kolegium Lekarzy Rodzinnych w Polsce. Wydawnictwo Lekarskie PZWL, Warszawa, 2003.

10. Woroń J, Engel Z, Filipczak-Bryniarska I, Wordliczek J. Anestezjologia i Ratownictwo. 2012;6:89-93.

11. Brunton L, Parker K, Blumenthal D, i wsp. Podręcznik Farmakologii i Terapii Goodmana i Gilmana. Wyd. Czelej 2010; s. 289.

12. Varga Z, Sabzwari SRA, Vargova V. Cardiovascular Risk of Nonsteroidal Anti-Inflammatory Drugs: An Under-Recognized Public Health Issue. Cureus. 2017 Apr 8;9(4):e1144. doi: 10.7759/cureus.1144. PMID: 28491485; PMCID: PMC5422108

13. Dworkin RH, O’Connor AB, Audette J, Baron R, Gourlay GK, Haanpää ML, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010 Mar;85(3 Suppl):S3-14. doi: 10.4065/ mcp.2009.0649. PMID: 20194146; PMCID: PMC2844007.

14. Suchorzewski M, Wujtewicz M. Opioidy w leczeniu bólu neuropatycznego. Medycyna Paliatywna w Praktyce. 2007;1(2):49-53.

15. Leppert W, Łuczak J. Polska Medycyna Paliatywna. 2002;1,2:93-105.

16. Wysocka-Bąkowska M. Leczenie doraźne migreny. Lek w Polsce. 2014;24(03):35-47.

17. http://leki.urpl.gov.pl/files/25_Tramal_Retard_200_tab_o_przedl_ uwaln_200.pdf.

18. Jung YS, Kim DK, Kim MK, Kim HJ, Cha I, Lee EW. Onset of analgesia and analgesic effi cacy of tramadol/acetaminophen and codeine/ acetaminophen/ibuprofen in acute postoperative pain: a single-center, single-dose, randomized,active-controlled, parallel-group study in a dental surgery pain model. Clin Ther. 2004;26(7):1037-1045.

19. Worthington I, Pringsheim T, Gawel MJ, Gladstone J, Cooper P, Dilli E, et al. Canadian Headache Society Acute Migraine Treatment Guideline Development Group. Canadian Headache Society Guideline: acute drug therapy for migraine headache. Can J Neurol Sci. 2013 Sep;40(5 Suppl 3):S1-S80. PMID: 23968886.

20. Murtagh FE, Chai MO, Donohoe P, Edmonds PM., Higginson IJ. The use of opioid analgesia in end-stage renal disease patients managed without dialysis: recommendations for practice. J Pain Palliat Care Pharmacother. 2007;21(2):5-16.

21.Twycross R, Wilcock A, Howard P. Palliative Care Formulary (PCF5), 5th Edition. Palliativedrugs.com Ltd, Nottingham, 2014.

22. Zylicz Z. Co przemawia za buprenorfiną w wyborze analgetyku opioidowego? Medycyna Paliatywna w Praktyce. 2013;7(3-4):85-90.

23. Schmidt-Hansen M, Taubert M, Bromham N, Hilgart JS, Arnold S. The effectiveness of buprenorphine for treating cancer pain: an abridged Cochrane review. BMJ Support Palliat Care 2016;6:292-306.

24. https://pubchem.ncbi.nlm.nih.gov/compound/Tapentadol#section=2D-Structure.

25. Schroder W, Tzschentke TM, Terlinden R i wsp. Synergistic interaction between the two mechanisms of action of tapentadol in analgesia. J. Pharmacol. Exp Ther. 2011;337(1):312–320.

26. Schroder W, De Vry JD, Tzschentke TM. i wsp. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain. Eur. J. Pain. 2010;14(8):814–821.

27. Ueberall MA, Mueller-Schwefe GH. Efficacy and tolerability balance of oxycodone/naloxone and tapentadol in chronic low back pain with a neuropathic component: a blinded end point analysis of randomly selected routine data from 12-week prospective open-label observations. J. Pain Res. 2016; 11(9):1001–1020.

28. Zajączkowska R, Kocot-Kępska M, Wordliczek J, Dobrogowski J. Tapentadol – nowy przedstawiciel ośrodkowo działających analgetyków klasy MOR-NRI. Terapia, numer specjalny. 2017:15-22.

29. Wild JE, Grond S, Kuperwasser B. i wsp. Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract. 2010;10(5):416–427.

30. Biondi DM, Xiang J, Etropolski M, Moskovitz B. Evaluation of Blood Pressure and Heart Rate in Patients with Hypertension Who Received Tapentadol Extended Release for Chronic Pain: A Post Hoc, Pooled Data Analysis Clin. Drug Investig. 2014;34:565–576.

31. Ueberall MA, Mueller-Schwefe GH. Efficacy and tolerability balance of oxycodone/naloxone and tapentadol in chronic low back pain with a neuropathic component: a blinded end point analysis of randomly selected routine data from 12-week prospective open-label observations. J. Pain Res. 2016;11(9):1001–1020.

32. Wiffen PJ, Derry S, Naessens K, Bell RF. Oral tapentadol for cancer pain. Cochrane Database Syst Rev. 2015 Sep 25;(9):CD011460. doi: 10.1002/14651858.CD011460.pub2.

33. Woroń J, Adamczyk A, Malec-Milewska M, Jakowicka-Wordliczek J. Stosowanie koanalgetyków u pacjentów z bólem neuropatycznym w przebiegu choroby nowotworowej. Medycyna Paliatywna w Praktyce. 2014;8(2):85-90.

34. Dworkin RH, O‘Connor AB, Backonja M i wsp. Pharmacological management of neuropathic pain: Evidence-based recomendations. Pain. 2007;132:237–251.

35. Mathieson S, Lin CC, Underwood M, Eldabe S. Pregabalin and gabapentin for pain. BMJ. 2020 Apr 28;369:m1315. doi: 10.1136/bmj. m1315. PMID: 32345589.

36. Magnowska M, Iżycka N, Kapoła-Czyż J, Romała A, Lorek J, Spaczyński M, Nowak-Markwitz E. Effectiveness of gabapentin pharmacotherapy in chemotherapy-induced peripheral neuropathy. Ginekol Pol. 2018;89(4):200-4. doi: 10.5603/GP.a2018.0034. PMID: 29781075.

37. Sandercock D, Cramer M, Wu J, Chiang YK, Biton V, Heritier M. Gabapentin extended release for the treatment of painful diabetic peripheral neuropathy: efficacy and tolerability in a double-blind, randomized, controlled clinical trial. Diabetes Care. 2009 Feb;32(2):e20. doi: 10.2337/dc08-1450. PMID: 19171730; PMCID: PMC6905491.

38. Taylor D, Paton C, Kerwin R. Prescribing guidelines. Informa Healthcare, London 2007.

39. Litt JZ. Psychiatric drug reactions and interactions. Taylor & Francis, London 2005.

40. Lorno V, Landi L, Porro GA, Egan CG, Calderini E. Long-term effect of oxycodone/naloxone on the management of postoperative pain after hysterectomy: a randomized prospective study. Minerva Anestesiol. 2020; 86(5): 488-497.

41. de Biase S, Pellitteri G, Gigli GL, Valente M. Advancing synthetic therapies for the treatment of restless legs syndrome. Expert Opin Pharmacother. 2019; 20(16): 1971-1980.

42. Clark K, Byrne PG, Hunt J, Brown L, Rowett D, Watts G, Lovell M, Currow DC. Pharmacovigilance in Hospice/Palliative Care: De--Prescribing Combination Controlled Release Oxycodone-Naloxone. J Palliat Med. 2020; 23(5): 656-661.